Bryan, Garnier & Co's News

Roche: Ocrelizumab: we are comfortable with our estimates

BUY – TOP PICKS, Fair Value CHF327 (+28%)
News published on
October Tuesday 13, 2015


Roche held a conference call yesterday to present in more detail the perspective offered by ocrelizumab on the back of data presented at the ECTRIMS meeting. We are very comfortable with our estimates of USD3bn peak sales in 2022 and we stick to this objective.


For more information, please contact marketing@bryangarnier.com